10-K: Precision BioSciences Reports Progress in Gene Editing Pipeline and Financial Results for 2024

Precision BioSciences advances its in vivo gene editing therapies, including PBGENE-HBV clinical trial initiation, and reports a net income of $7.2 million for the year ended December 31, 2024.

Summary

• Precision BioSciences is a clinical-stage gene editing company focused on in vivo therapies for genetic and infectious diseases using its ARCUS platform.
• The company's lead wholly-owned program, PBGENE-HBV, is in a Phase 1 clinical trial (ELIMINATE-B) actively enrolling patients in multiple countries, with plans to initiate clinical activities in the U.S. following IND approval in March 2025.
• PBGENE-HBV demonstrated a substantial reduction in HBsAg in two of the three participants following the first administration at the lowest dose.
• The PBGENE-3243 program, a potential treatment for m.3243 associated mitochondrial disease, is expected to have an IND and/or CTA application submitted in 2025.
• In April 2024, Prevail Therapeutics terminated the amended and restated development and license agreement, resulting in the return of three programs to Precision BioSciences.
• iECURE reported a complete clinical response in the first infant dosed with ECUR-506 in the Phase 1/2 OTC-HOPE study.
• The company had a net income of $7.2 million for the year ended December 31, 2024, and an accumulated deficit of $482.5 million.
• Existing cash and cash equivalents, expected operational receipts, and availability of the ATM facility are expected to fund operating expenses into the second half of 2026.
• The company is subject to the 'Baby Shelf Rule', limiting the amount of funds it can raise through primary public offerings until its public float exceeds $75 million.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While there's progress in the clinical pipeline and a return to profitability, there are also risks related to funding, competition, and regulatory hurdles. The positive financial results and clinical advancements are encouraging, but the challenges ahead temper the overall sentiment.

Positives

• PBGENE-HBV was well tolerated in the first cohort of the ELIMINATE-B trial, with no Grade 2 treatment-related adverse events or serious adverse events reported.
• Preclinical data supports the ability of ARCUS to make efficient, durable, and targeted elimination edits.
• ARCUS has demonstrated the ability to achieve high-efficiency gene insertion, gene replacement, and base correction via HDR.
• iECURE reported a complete clinical response in the first infant dosed with ECUR-506 in the Phase 1/2 OTC-HOPE study.
• The company has an exclusive in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG.
• The company has granted Caribou Biosciences, Inc. a non-exclusive, worldwide license to one of its foundational cell therapy patent families for use with CRISPR-based therapies in the field of human therapeutics.

Negatives

• Prevail Therapeutics terminated the amended and restated development and license agreement, resulting in the return of three programs to Precision BioSciences.
• The company is subject to the 'Baby Shelf Rule', limiting the amount of funds it can raise through primary public offerings until its public float exceeds $75 million.

Risks

• The company has incurred significant operating losses since its inception and expects to continue to incur losses for the foreseeable future.
• The company will need substantial additional funding, and if it is unable to raise a sufficient amount of capital when needed on acceptable terms, or at all, it may be forced to delay, reduce or eliminate some or all of its research programs, product development activities and commercialization efforts.
• ARCUS is a novel technology, making it difficult to predict the time, cost and potential success of product candidate development.
• Adverse public perception of genome editing may negatively impact the developmental progress or commercial success of products that the company develops alone or with collaborators.
• The company faces significant competition in industries experiencing rapid technological change, and there is a possibility that its competitors may achieve regulatory approval before it or develop product candidates or treatments that are safer or more effective than its, which may harm its financial condition and its ability to successfully market or commercialize any of its product candidates.
• The regulatory landscape that will apply to development of therapeutic product candidates by the company or its collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.
• Clinical trials are difficult to design and implement, expensive, time-consuming and involve an uncertain outcome, and the inability to successfully and timely conduct clinical trials and obtain regulatory approval for its product candidates would substantially harm its business.
• Any product candidates that the company or its collaborators or other licensees may develop will be novel and may be complex and difficult to manufacture, and if the company experiences manufacturing problems, it could result in delays in development and commercialization of such product candidates or otherwise harm its business.
• Even if the company obtains regulatory approval for any products that it develops alone or with collaborators, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense.
• Even if any product the company develops alone or with collaborators receives marketing approval, such product may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
• The company's failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of its common stock.

Future Outlook

Precision BioSciences expects existing cash and cash equivalents, expected operational receipts, and availability of the ATM facility will be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2026. The company expects its cash runway to be sufficient to achieve first-in-human Phase 1 clinical data for two of its wholly-owned programs.

Management Comments

• The company is solely focused on leveraging its ARCUS genome editing platform to advance in vivo gene editing programs that go beyond gene knockouts in the liver and carry out sophisticated edits such as gene insertions, gene excision, and gene elimination in human therapeutics.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products. Precision BioSciences principally competes with others developing and utilizing genome and epigenomic editing technology in the human health sector.

Comparison to Industry Standards

• Precision BioSciences competes with companies such as Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Prime Medicine, Tune Therapeutics, and Verve Therapeutics.
• Many of Precision BioSciences' current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and marketing approved products than Precision BioSciences does.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through successful development and commercialization of gene editing therapies.
• Employees: Continued employment and potential for professional growth within a growing biotechnology company.
• Patients: Potential access to novel therapies for genetic and infectious diseases.
• Collaborators: Opportunities for collaboration and revenue sharing through strategic partnerships.

Next Steps

• Initiate Phase 1 clinical activities in the U.S. for PBGENE-HBV following IND approval in March 2025.
• Submit an IND and/or CTA application for PBGENE-3243 in 2025.
• iECURE expects to finish enrollment in the OTC-HOPE study in 2025 and provide complete data for the program in the first half of 2026.

Key Dates

Keywords

gene editing, ARCUS, in vivo, PBGENE-HBV, PBGENE-3243, clinical trial, hemoglobinopathies, mitochondrial disease, Novartis, iECURE, biotechnology, pharmaceuticals